William Blair analyst Brandon Vazquez has maintained their bullish stance on ZTS stock, giving a Buy rating on November 12.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brandon Vazquez has given his Buy rating due to a combination of factors influencing Zoetis’s current and future market position. Despite facing challenges from increased competition and recent commercial setbacks with Librela, Vazquez sees potential for recovery and growth. The upcoming innovation day is anticipated to provide crucial updates on Zoetis’s pipeline and strategies, which could bolster investor confidence.
Vazquez is particularly focused on clinical updates for key products like Librela and Solensia, which could return to growth, and new developments such as Lenivia, which may drive future expansion. Additionally, long-term prospects are promising with potential advancements in oncology and renal therapies. These factors collectively contribute to a positive outlook on Zoetis’s stock, justifying the Buy rating.
In another report released on November 12, BTIG also maintained a Buy rating on the stock with a $160.00 price target.